C5-targetting monoclonal antibody clears Phase I trials
Biotechnology company ImmunAbs has announced the successful completion of a Phase I clinical trial for IM-101, a humanised monoclonal antibody targeting complement C5. The complement system is widely acknowledged for its critical involvement in autoimmune diseases. The randomised, double-blind, placebo-controlled trial was conducted to… Read More